Ysios Capital — 2024 Investments

1 investments dated 2024 · listed companies and verified rows first · show all

Memo Therapeutics AGmemo-therapeutics.com inMay 2024✓ verifiedacquired by Clementia

Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases.

BiotechMedical DevicesZurich, CH

Co-investorsKurma Partners Pureos Bioventures Adjuvant Capital Fresenius Medical Care Ventures Verve Ventures redalpine

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.